{
  "id": "5c7019557c78d6947100005f",
  "type": "yesno",
  "question": "Does an interferon (IFN) signature exist for SLE patients?",
  "ideal_answer": "Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. An IFN-I score (positive or negative), as a measure of IFN-I activation, is assessed using the expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29850618",
    "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
    "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
    "http://www.ncbi.nlm.nih.gov/pubmed/28830352"
  ],
  "snippets": [
    {
      "text": "Interferon regulatory factor 7 activation correlates with the IFN signature and recurrent disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In SLE post-transplant, recurrent disease activity and induction of IRF7 protein expression correlated with activation of the IFN signature.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21576205",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830352",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28830352",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We found that cDCs from prediseased TCSle male mice express the IFN signature as female TCSle cDCs do. Estrogens are necessary but not sufficient to express this IFN signature, but high doses of E2 can compensate for other steroidal components.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850618",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conventional DCs from Male and Female Lupus-Prone B6.NZM Sle1/Sle2/Sle3 Mice Express an IFN Signature and Have a Higher Immunometabolism That Are Enhanced by Estrogen.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29850618",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Type I IFN signature in childhood-onset systemic lupus erythematosus",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " Interferon type I (IFN-I) plays a pivotal role in the pathogenesis of SLE. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The IFN-I score (positive or negative), as a measure of IFN-I activation, was assessed using real-time quantitative PCR (RT-PCR) expression values of IFN-I signature genes (IFI44, IFI44L, IFIT1, Ly6e, MxA, IFITM1) in CD14+ monocytes of cSLE patients and healthy controls (HCs)",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29321042",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}